Array BioPharma Inc. (ARRY)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 13.06 / 47.98
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

Mylan Shares Surge Amid Reports of Off-Patent Drug Combination with Pfizer

Mylan Shares Surge Amid Reports of Off-Patent Drug Combination with Pfizer

Mylan shares were indicated sharply higher Monday amid reports the generic drugs group is set to create a separate business with Pfizer for off-patent pharmaceuticals.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

Lifshitz & Miller LLP Announces Investigation Of Array BioPharma Inc., C&J Energy Services, Inc., Liberty Expedia Holdings, Inc., And Raytheon Company, Shutterfly, Inc., Sotheby's And Stewardship Financial Corporation, And Zimmer Biomet Holdings, Inc.

Lifshitz & Miller LLP Announces Investigation Of Array BioPharma Inc., C&J Energy Services, Inc., Liberty Expedia Holdings, Inc., And Raytheon Company, Shutterfly, Inc., Sotheby's And Stewardship Financial Corporation, And Zimmer Biomet Holdings, Inc.

NEW YORK, June 27, 2019 /PRNewswire/ -- Array BioPharma Inc. (ARRY) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the proposed sale of ARRY to Pfizer, Inc.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

URGENT ALERT: Monteverde & Associates PC Launches An Investigation Regarding The Following Merger

URGENT ALERT: Monteverde & Associates PC Launches An Investigation Regarding The Following Merger

NEW YORK, June 21, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: BioScrip, Inc.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition

SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition

NEW YORK, June 18, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (NASDAQ: ARRY) in connection with the proposed...

Stocks End Slightly Higher in Cautious Trading Ahead of Federal Reserve Meeting

Stocks End Slightly Higher in Cautious Trading Ahead of Federal Reserve Meeting

Stocks end moderately ahead as investors are adopting a cautious stance heading into this week's Federal Reserve meeting.

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

I'm inclined to add to Disney on today's weakness.

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.

Pfizer To Acquire Array BioPharma

Pfizer To Acquire Array BioPharma

- Proposed acquisition strengthens Pfizer's innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term

Pfizer To Acquire Array BioPharma

Pfizer To Acquire Array BioPharma

Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Nio, Hexo, Microsoft, Adobe: 'Mad Money' Lightning Round

Nio, Hexo, Microsoft, Adobe: 'Mad Money' Lightning Round

A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.

Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)

Don't Get Complacent: Cramer's 'Mad Money' Recap (Tuesday 6/4/19)

Key oscillator signal works again, but that's no reason to nod off, Jim Cramer says.

Array BioPharma To Present At The Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference

Array BioPharma To Present At The Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference

BOULDER, Colo., June 4, 2019 /PRNewswire/ -- Array BioPharma Inc.

Array BioPharma To Present At The Jefferies 2019 Global Healthcare Conference

Array BioPharma To Present At The Jefferies 2019 Global Healthcare Conference

BOULDER, Colo., May 29, 2019 /PRNewswire/ -- Array BioPharma Inc.

Array BioPharma Announces Presentation Of Updated Overall Survival From The Phase 3 COLUMBUS Trial Of BRAFTOVI MEKTOVI In Advanced BRAF-mutant Melanoma At 2019 ASCO Annual Meeting

Array BioPharma Announces Presentation Of Updated Overall Survival From The Phase 3 COLUMBUS Trial Of BRAFTOVI MEKTOVI In Advanced BRAF-mutant Melanoma At 2019 ASCO Annual Meeting

- Consistent with prior readouts, BRAFTOVI + MEKTOVI demonstrates 33.6 months median overall survival with longer median follow up over 48 months -

Array BioPharma To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference

Array BioPharma To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference

BOULDER, Colo., May 9, 2019 /PRNewswire/ -- Array BioPharma Inc.

Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2019

Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2019

- Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million in the third quarter -

Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2019 On May 7, 2019

Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2019 On May 7, 2019

BOULDER, Colo., April 30, 2019 /PRNewswire/ -- Array BioPharma Inc.